Immuneering (IMRX) Cash & Equivalents (2020 - 2026)

Immuneering's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $47.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 31.94% year-over-year to $47.3 million in Q1 2026; TTM through Mar 2026 was $47.3 million, a 31.94% increase from a year earlier, with the FY2025 full-year figure at $128.6 million, up 255.92% from the prior year.
• Cash & Equivalents eased to $47.3 million in Q1 2026 per IMRX's latest filing, from $128.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $227.6 million in Q3 2025 and bottomed at $26.4 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $68.0 million (2023), against an average of $76.1 million.
• Biggest YoY gain for Cash & Equivalents was 403.4% in 2025; the steepest drop was 55.87% in 2025.
• Year by year, Cash & Equivalents stood at $72.6 million in 2022, then dropped by 18.22% to $59.4 million in 2023, then plunged by 39.16% to $36.1 million in 2024, then soared by 255.92% to $128.6 million in 2025, then slumped by 63.22% to $47.3 million in 2026.
• Per Business Quant, the three latest IMRX Cash & Equivalents figures stand at $47.3 million (Q1 2026), $128.6 million (Q4 2025), and $227.6 million (Q3 2025).